Abstract: The present invention relates to a compound of the formula I wherein R1 to R6, A, B, n and m are as defined herein. Such novel sulfonyl amide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.

Abstract: A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering. CasM proteins are capable of targeting and cleaving single-stranded RNA.

Abstract: A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering. CasM proteins are capable of targeting and cleaving single-stranded RNA.

Abstract: An aquaculture system includes a pen configured to be disposed in a body of water and configured to at least temporarily store aquatic animals during development. A control system is configured to receive electric power from a power source and is configured to provide electric power to a pumping mechanism coupled to the pen such that the pumping mechanism provides a flow of water through the pen. A set of buoyancy tanks are coupled to the pen. A portion of the control system is in fluid communication with the set of buoyancy tanks and is configured to adjust a volume of fluid in at least one buoyancy tank to move the pen from a first position in which the pen is partially submerged in the body of water to a second position in which the pen is fully submerged in the body of water.

Abstract: Dual phase membranes include a porous support providing a solid phase having a matrix of connected pores, and a liquefiable ion transport phase within the pores of the porous support. The ion transport phase is formed of at least one alkali metal hydroxide, and at least one oxide ion transport agent providing a source of ions selected from the group consisting of borate ions, nitrate ions, phosphate ions, vanadate ions, niobate ions or sulfate ions. The at least one alkali metal hydroxide may be selected from the group consisting of NaOH, KOH, LiOH, RbOH, CsOH and mixtures thereof. The oxide ion transport agent is preferably present in the ion transport phase in an amount between about 1 to about 30 molar %. Substantially lower operational temperatures may be realized when the membrane is used to separate CO2 from a feed gas.

Abstract: Processes are provided which pyrolytically extract hydrochloric acid from a magnesium ion-rich salt mixture. In this regard, a supply of the magnesium ion-rich salt mixture (e.g., bittern) may be directed to a pyrolytic chamber where it is contacted with heated gas (e.g., combustion flue gas) at a sufficient temperature and for a sufficient time to form a vapor product stream comprised of hydrochloric acid and an insoluble pyrolyzed mixed salt stream comprised of magnesium hydroxide and sodium sulfate decahydrate. The solid pyrolyzed mixed salt stream may be separated into separate product streams comprising the insoluble magnesium hydroxide and remaining soluble salt fractions, while the vapor product stream of hydrochloric acid from the pyrolytic chamber may be condensed form an aqueous HCl solution. The magnesium ion rich salt mixture may be dehydrated prior to pyrolysis to achieve magnesium ions in a tetrahydrate state or lower (e.g., a monohydrate to a trihydrate state).

Abstract: A compound compound having the structure: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein A, A? and A? are independently O, C?O, C—R? or N—R?, where R? and R? may independently be H, amino, —NR7COR6, COR6, —CONR7R8, C1-C6 alkyl, or hydroxy(C1-C6 alkyl), and R? may be present or absent, and is present where the rules of valency permit, and where not more than one of A, A? and A? is O or C?O; R0 and R are independently H, Br, Cl, F, or C1-C6 alkyl; R1 is H, C1-C6 alkyl, or hydroxy(C1-C6 alkyl); R2 is selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, hydroxy(C1-C6 alkyl), phenyl(C1-C6 alkyl), formyl, heteroaryl, heterocyclic, —COR6, —OCOR6, —COOR6, —NR7COR6, —CONR7R8, and —(CH2)n—W, where W is cyano, hydroxy, C3-C8 cycloalkyl, —SO2NR7R8, and —SO2—R9, where R9 is C1-C6 alkyl, C3-C8 cycloalkyl, heteroaryl, or heterocyclic; wherein each of said alkyl, cycloalkyl, heterocyclic, or heteroaryl ma

Abstract: The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.

Abstract: There is a method for treating a psoriasis. A compound is administered in a therapeutically effective amount to a subject suffering therefrom. The compound has the structure or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof.

Abstract: This disclosure provides for compositions and methods for the use of nucleic acid-targeting nucleic acids and complexes thereof. Genome engineering can refer to altering the genome by deleting, inserting, mutating, or substituting specific nucleic acid sequences. The altering can be gene or location specific. Genome engineering can use nucleases to cut a nucleic acid thereby generating a site for the alteration. Engineering of non-genomic nucleic acid is also contemplated.

Abstract: The present invention relates to a compound of the formula I wherein R1 to R6, A, B, n and m are as defined herein. Such novel sulfonyl amide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.

Abstract: The present disclosure relates to an electrical energy storage apparatus. The apparatus has an interpenetrating, three dimensional periodic structure formed from an ionically conductive solid electrolyte material having a plurality of interpenetrating, non-planar channels. The interpenetrating, non-planar channels are made up of a first plurality of channels filled with an anode material, a second plurality of channels adjacent the first plurality of channels and interpenetrating with the first plurality of channels, and filled with a cathode material, and a third plurality of channels adjacent to, and interpenetrating with, one of the first and second pluralities of channels, and filled with a material to form a separator. The first, second and third channels form a spatially dense, three dimensional structure. A first non-flat current collector layer is incorporated which is in communication with the first plurality of channels, and which forms a first electrode.

Abstract: A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering. CasM proteins are capable of targeting and cleaving single-stranded RNA.

Abstract: This disclosure provides for compositions and methods for the use of nucleic acid-targeting nucleic acids and complexes thereof.

Abstract: The present disclosure relates to an electrical energy storage apparatus which forms an interpenetrating, three dimensional structure. The structure may have a first non-planar channel filled with an anode material to form an anode, and a second non-planar channel adjacent the first non-planar channel filled with a cathode material to form a cathode. A third non-planar channel may be formed adjacent the first and second non-planar channels and filled with an electrolyte. The first, second and third channels are formed so as to be interpenetrating and form a spatially dense, three dimensional structure. A first current collector is in communication with the first non-planar channel and forms a first electrode, while a second current collector is in communication with the second non-planar channel and forms a second electrode. A separator layers separates the current collectors.

Abstract: A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering. CasM proteins are capable of targeting and cleaving single-stranded RNA.

Abstract: In one embodiment, a method for separating acidic gases from a gas mixture includes exposing the gas mixture to a separation membrane at an elevated temperature, where the separation membrane includes a porous support and at least one molten alkali metal hydroxide disposed within pores of the porous support.

Abstract: In one embodiment, a separation membrane includes: a porous support structure, wherein the porous support structure comprises a system of continuous pores connecting an inlet of the separation membrane to an outlet of the separation membrane; and at least one alkali metal hydroxide disposed within pores of the porous support structure. Other aspects and embodiments of the disclosed inventive concepts will become apparent from the detailed description, which, when taken in conjunction with the drawings, illustrate by way of example the principles of the invention.

Abstract: A compound having the structure: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein variables are defined in the specification. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations thereof with other therapeutic agents.

Abstract: The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylam ides and analogues thereof, having the structure: or a pharmaceutically acceptable salt thereof, as set forth in the Description. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.